BOSTON, November 07, 2022–( COMPANY WIRE)– Cerveau Technologies, Inc. today revealed a license contract with LEXEO Rehabs, Inc. (LEXEO), which will make it possible for LEXEO to utilize Cerveau’s [F-18] MK-6240, an investigational imaging representative, in Positron Emission Tomography (FAMILY PET) scans to evaluate the status and development of neurofibrillary tangles (NFTs) in the brain. NFTs comprised of aggregated tau protein are a trademark of numerous neurodegenerative illness, consisting of Alzheimer’s illness.
The partnership is concentrated on utilizing [F-18] MK-6240 as a biomarker in LEXEO’s continuous scientific research study Procedure LX1001-01, an investigational gene treatment prospect for APOE4-associated Alzheimer’s illness.
” Cerveau is pleased to be dealing with LEXEO to much better comprehend Tau animal’s usage in supporting restorative trials,” stated Rick Hiatt, Ceo, Cerveau Technologies, Inc. “The partnership with LEXEO is another crucial advance in our technique of broadening our global network of crucial scholastic and pharmaceutical market partners in order to assist combat versus neurodegenerative illness.”
About Cerveau Technologies, Inc.
Cerveau’s vision is to internationally establish diagnostics and innovation that favorably effect clients with neurodegenerative conditions consisting of Alzheimer’s illness.
View source variation on businesswire.com: https://www.businesswire.com/news/home/20221107005421/en/
Contacts
Cerveau Technologies, Inc.
Rick Hiatt, 617-906-2715
[email protected]